Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
Janus kinase inhibitors (JAKis) have revolutionized the treatment landscape for various inflammatory and autoimmune diseases since their introduction in 2012. The expanded indications of JAKis have raised concerns about the associated risk of thrombosis, venous thromboembolic events (VTEs), and arte...
Saved in:
Main Authors: | Yachar Dawudi, Samuel Benarroch, Hélène Helfer, David M. Smadja, Isabelle Mahé |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | Research and Practice in Thrombosis and Haemostasis |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037924003625 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
by: Huibin Yang, et al.
Published: (2025-12-01) -
Venous thromboembolism in bullous pemphigoid: current evidence and update on systematic review
by: Atheer G. Almutairi, et al.
Published: (2025-01-01) -
Evaluation of Risk Factors of Venous Thromboembolism in Imam Sadiq Teaching Hospital at Babylon City
by: Intisar Mahdi Kadhim Almurshedi, et al.
Published: (2022-11-01) -
Biological Aging and Venous Thromboembolism: A Review of Telomeres and Beyond
by: Rafaela Vostatek, et al.
Published: (2024-12-01) -
PERIOPERATIVE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ROUTINE ONCOSURGERY
by: V. E. Khoronenko, et al.
Published: (2016-12-01)